PerkinElmer
check quantity

Epic C18 LC Columns - 150 mm, 4.6 mm I.D., 3 μm

Epic C18 is a highly inert phase due to its superior base deactivation. As a result of the high-density bonding levels (> 4 µmol/m2), Epic C18 demonstrates superior peak shapes for the most demanding applications. This phase provides exceptional peak shape and selectivity over a wide range of compounds and pH and is the workhorse HPLC and UHPLC phase for RP small molecule analysis. It can be used with basic, neutral and acidic analytes.

Part Number
Inner Diameter
Particle Size
List Price
Your Price
Quantity
135191-EC18
4.6 mm
3.0 µm
646.00 USD
 
more
135291-EC18
4.6 mm
5.0 µm
600.00 USD
 
more
Buy Now

Please enter valid quantity

Please log in to add favorites.

NULL OR EMPTY CART

Overview

The Epic line our latest range of LC columns, based on high density monomerically bonded phases produced through a proprietary bonding process. Epic HPLC and UHPLC columns are compatible with a wide range of organic modifiers and buffers and stable over a wide pH range. All Epic products use an ultra-high purity metal free silica and undergo strict quality control testing. For flexibility, we offer a wide range of column sizes as well being fully scalable from analytical to preparative dimensions.

Features and Benefits:

  • Ultra-high purity silica for improved peak shape, especially for basic compounds
  • Extensive range of stationary phase chemistries with innovative bonding chemistry to enhance method development
  • High density bonding produces columns with better pH stability, increased sample loading and better lot-to-lot reproducibility
  • Extended pH stability across commonly used mobile phase buffers
  • Microbore to preparative dimensions available to allow flexibility and full scalability

Specifications

Inner Diameter 4.6 mm
Length 150.0 mm
Particle Size 3.0 µm
Phase C18
Resources, Events & More
  • All

Application Brief

HPLC Analysis of Levetiracetam Using Epic C18, Epic C18-SD, and Epic Polar Columns in Accordance with the USP

Levetiracetam was approved for medical use in the United States in 1999 and is available as a generic medication.1 Levetiracetam is a novel anticonvulsant agent used as an adjunct medication to manage partial onset, myoclonic, and generalized tonic-clonic seizures in patients with epilepsy. It is ...

PDF 361 KB
HPLC Analysis of Oleanolic Acid and Ursonic Acid in Eriobotrya Japonica Leaf

Eriobotrya japonica leaf is included in the Chinese Pharmacopoeia and is widely used as a medicinal material in traditional treatment of a variety of chronic diseases in China and other East Asian countries. Phytochemical investigations showed that its main components are essential oil, triterpen ...

PDF 1 MB